CD4 and neoplasm: Different preclinical studies reported that PARP inhibitors significantly increased tumor infiltrating CD4+/CD8+ T cells which were activated by the stimulator of interferon genes (STING) pathway and recruited to tumors by tumor-specific neoantigens when combined with ICIs [6, 7].